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Abstract: 
 
Chemokines are critically involved in the development of chronic inflammatory-associated 
diseases such as atherosclerosis. We hypothesised that targeted delivery of compounds to the 
surface of activated endothelial cells (EC) interferes with chemokine/receptor interaction and 
thereby efficiently blocks inflammation. We developed PEGylated target-sensitive liposomes 
(TSL) encapsulating a CCR2 antagonist (Teijin compound 1) coupled with a specific peptide 
recognized by  endothelial VCAM-1 (Vp-TSL-Tj). TSL were characterized for size (by dynamic 
light scattering), the amount of peptide coupled at the surface of liposomes and Teijin release (by 
HPLC). We report that Vp-TSL-Tj binds specifically to activated EC in vitro and in vivo, release 
the entrapped Teijin and prevent the transmigration of monocytes through activated EC. This is 
the first evidence that nanocarriers transporting and releasing chemokine inhibitors at specific 
pathological sites reduce the chemokine-dependent inflammatory process. 
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Abbreviations: 
CCR2, CC chemokine receptor 2; EC, endothelial cells; DOPE, 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine; DOPA, 1,2-dioleoyl-sn-glycero-3-phosphate; PEG-DSPE, 1,2-distearoyl-
sn-glycero-3-phosphoetanolamine-N-[poly(ethylene glycol)-2000]; Mal-PEG-DSPE, 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000]; TSL, 
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target sensitive liposomes; Vp-TSL, VCAM-1 recognizing peptide coupled to target sensitive 
liposomes; Vp-TSL-Tj,  VCAM-1 recognizing peptide coupled to target sensitive liposomes 
encapsulating Teijin, TSL-Tj (target sensitive liposomes encapsulating Teijin without VCAM-1 
recognizing peptide coupled); Vp-CL, VCAM-1 recognizing peptide coupled to conventional 
liposomes; Vp-CL-Tj, VCAM-1 recognizing peptide coupled to conventional liposomes 
encapsulating Teijin 
 
 
1. Introduction 
 
Atherosclerotic plaque formation is an inflammatory process that is associated with expression of 
a specific repertoire of chemokines and cell adhesion molecules by endothelial cells (EC).1 Both 
factors  contribute to leukocyte recruitment to the developing atheroma. Chemokines are small, 
highly specialized polypeptides that function as modulators of cellular traffic through their 
interactions with G protein-coupled receptors at a spatially defined site.2 Chemokines bind to 
glycosaminoglycans (GAGs) present on the EC membrane and guide leukocyte entry into the 
vessel wall. Based on the key importance of chemokines in the development of atherosclerosis, a 
pharmacological interference at the level of chemokines may open new avenues in the 
prevention and treatment of this disorder. Thus, functional manipulation of the chemokine 
system using chemokine antagonists (CA) or chemokine receptor antagonists (CRA) constitutes 
an important therapeutic option to prevent the accumulation of inflammatory immune cells that 
drives atherogenesis. However, systemic administration of chemokine antagonists or 
interventions in the function of one or more chemokines have potentially a high risk of side 
 4 
effects, such as impaired host defence against pathogens. Experimental and clinical testing of 
potential inhibitors of chemokines and their receptors for the treatment of inflammatory diseases 
revealed detrimental immunological effects.3 Therefore, there is a need for the development of 
new and innovative therapeutic approaches or strategies to manipulate selectively specific 
chemokine(s) function in a particular pathophysiological context with few or no adverse effects 
on the immune system. We hypothesised that the local targeted delivery of CA or CRA at 
specific sites utilizing appropriately designed carriers may constitute a novel and improved 
strategy to hold back or interrupt a confined inflammatory process. 
 Despite progress in the field of targeted carrier technologies, different approaches require 
a design of carriers with specific properties with respect to tissue targeting. To interfere with the 
chemokine axis within the local microenvironment at the EC surface, the carrier system should 
have the potential to: i) efficiently entrap drugs (CA or CRA), ii) target sequences of specific 
receptors on the activated endothelial surface, and iii) have a specific release mechanism for the 
drug cargo at the site of adhesion prior to cellular uptake. In this respect, liposomes appear most 
promising thanked to their tunable properties in drug loading and release characteristics as well 
as their manifold coupling technologies for specific homing devices. 
 Vascular targeting of liposomes was previously applied in inflammatory-related diseases, 
usually combined with targeting EC adhesion receptors.4-8 The shortcoming of this approach is 
that the liposomes were predominantly taken up by EC, an effect entirely inadequate when 
inhibition of chemokine/chemokine receptor interaction at the cell's surface is sought after.9-11 To 
circumvent this problem, we revisited an old principle of target-triggered release of drugs from 
target-sensitive liposomes (TSL) initially described by Huang and colleagues. 14-17 These carriers 
have a specific phospholipid bilayer composition, which upon target recognition and binding 
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exhibit destabilization that is followed immediately by payload release.12-15 Taking advantage of 
these properties, we hypothesized that these type of liposomes modified accurately for our aim, 
could be employed successfully in the chemokine targeting approaches. Here we demonstrate 
that the principle of TSL combined with PEGylation leads to particles that characteristically have 
long storage and circulation time and concomitantly maintain the trigger-release properties. We 
provide evidence that PEGylated TSL coupled with a recognizing peptide directed specifically 
against vascular cell adhesion molecule-1 (VCAM-1) and encapsulating an antagonist to CCR2 
namely Teijin compound 1, (Vp-TSL-Tj) bind specifically to activated EC in culture and inhibit 
the ensuing adhesion and transendothelial migration of monocytes. In ApoE-deficient mouse, 
Vp-TSL target specifically aortic plaque endothelial VCAM-1 and Teijin compound 1 reduces 
the mouse monocyte/macrophage cell line (RAW 264.7) adhesion/infiltration into the aorta. This 
is a novel and promising approach to target initial inflammatory process that is common critical 
event in numerous major diseases, including atherosclerosis.  
 
2. Materials and methods 
 
2.1. Reagents 
 
Reagents were obtained from following sources: 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphate (sodium salt) (DOPA), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] (Mal-
PEG-DSPE), 1,2-distearoyl-sn-glycero-3-phosphoetanolamine-N-[poly(ethylene glycol)-2000] 
(PEG-DSPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
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sulfonyl) (ammonium salt) (Rhodamin-PE) and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) from Avanti Polar Lipids (Alabaster, AL/USA), mouse anti-human 
VCAM-1, irrelevant mouse IgG1 and rhVCAM-1 Fc chimera from R&D Systems (Biomedica 
Medizinprodukte Romania SRL), Dulbecco’s modified Eagle’s medium (DMEM), fetal calf 
serum (FCS) from Gibco BRL (Antisel Selidis Ro SRL), cell culture plates from Corning (New 
York, NY/USA), black 96-well plates from Nalge NUNC International (Rochester, USA), 
peptide with high affinity for VCAM-1 (VHPKQHRGGSKGC) was synthesized by GeneCust 
(Dudelange, Luxembourg), Amicon centrifugal filter columns with a cutoff of 100 kDa from 
Millipore (Merk Romania SRL), transmigration chambers from Costar Europe Ltd. 
(Badhoevedorp, The Netherlands), tris (2-carboxyethyl)phosphine (TCEP), phospholipid 
determination, bicinchoninic acid protein assay kit, as well as all other chemicals were from 
Sigma-Aldrich  (Redox Lab Supplies Com S.R.L.).  
 
2.2. Preparation of VCAM-1 directed, PEG-stabilized Target-Sensitive Liposomes (Vp-TSL)  
 
 2.2.1. Preparation of TSL 
 
PEG-stabilized TSL were prepared by a mixture of DOPE, DOPA and a functionalized 
phospholipidic anchor (Mal-PEG-DSPE) used to covalently couple the peptide with affinity for 
VCAM-1 to the liposome surface. As control, non-sensitive, conventional liposomes (CL) were 
prepared using POPC and cholesterol instead of DOPE and DOPA (POPC:Chol:Mal-PEG-
DSPE:DSPE-PEG at a molar ratio 60:35:2:3 mol%). Unilamellar liposomes with different 
composition and lipid ratio (as indicated in supplementary table 1, please visit 
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http://pubs.acs.org) were obtained by extruding multilamellar vesicles through polycarbonate 
membranes as previously described.16 Briefly, the mixture of phospholipids in chloroform was 
dried in a rotary evaporator under reduced pressure. The resulted lipid film was hydrated with a 
solution containing the substance to be encapsulated into liposomes, i.e. phosphate buffered 
saline (PBS), calcein or CCR2 antagonist, to reach the final lipid concentration of 10 µmol/ml. 
The resulting multilamellar vesicles, obtained by thorough mixing the aqueous solutions of 
lipids, were extruded 10 times through a 100 nm polycarbonate membrane using a Mini-Extruder 
(Avanti Polar Lipids, Alabaster, AL/USA).  
To fluorescently label the phospholipid bilayers of liposomes, 1 mol % Rhodamin-PE was added 
as an ethanol solution subsequent to liposomes preparation.  
For content release studies, the liposomes were prepared by hydration of the phospholipid 
mixture with a solution of 100 mM calcein or CCR2 antagonist (Teijin compound 1). Removal 
of non-incorporated calcein or CCR2 antagonist was accomplished by gel filtration on a 
Sephadex G-50 column using as an eluting solution the following buffer: 10 mM Na2HPO4, 10 
mM NaH2PO4, 2mM EDTA and 30 mM NaCl, pH:6.7 (coupling buffer). 
 
 2.2.2. Coupling of VCAM-1 recognizing peptide to the surface of TSL 
 
A VCAM-1 binding peptide with the amino acids sequence VHPKQHRGGSKGC (described by 
Kelly et al.17) has been coupled to the maleimide group at the distal end of PEG by sulfhydryl-
maleimide as previously described.18 Before coupling, the peptide was reduced with Tris (2-
carboxyethyl) phosphine (TCEP) (2 hours at room temperature) that breaks the disulfide bond 
between peptides and activates the sulfhydryl group. The excess TCEP was removed by dialysis 
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(using cellulose ester membrane with a cut-off of 500-1000 Da) against coupling buffer, 
overnight at 4°C. Then, an aliquot of the solution of the VCAM-1 recognizing peptide in 
coupling buffer was added at a concentration of 10 µg peptide/µmol total lipid to maleimide 
functionalized PEG-DSPE containing liposomes and incubated overnight at room temperature 
under shaking. To saturate non-reacted maleimide, 1 mM L-cystein was added for 30 minutes at 
room temperature and the unbound peptide was removed employing centrifugal filter columns 
with a cut off 100 kDa. Control liposomes (with no peptide coupled) were prepared from the 
same lipid mixture in which the reactive maleimide groups were blocked with L-cystein. 
The amount of peptide coupled at the surface of liposomes was quantified by HPLC employing a 
UHPLC-Agilent 1290 Infinity with a Zorbax SB C18 2.1x100 mm, 1.8 µm column and a 
gradient of 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B) (from 1% B until 26% B in 
A for 10 minutes). 
 
2.3. Vp-TSL characterization 
 
Liposomes prepared as described above were characterized for their physical properties (size, 
temperature and serum-stability) and functionality (binding to the target, content release). 
 
 2.3.1. Size 
 
The size distribution and the average diameter of the resulting liposomes was determined by 
photon correlation spectroscopy using Nicomp submicron particle analyzer model 380 (Nicomp 
Inst Corp, Santa Barbara, CA) and the multi-modal distribution. The vesicle suspensions were 
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diluted with fresh (0.22 µm-filtrated) PBS in order to reach a count rate of 250 to 350 kHz. The 
instrument parameters were set as follows: automatic choice of channel width, vesicle mode, 
volume weighting and automatic change from Gaussian distribution mode to multimodal mode if 
the value of Chi-squared exceeded 3.00. 
  
 2.3.2. Temperature-dependent stability of Vp-TSL 
 
 The stability of Vp-TSL at 4°C (storage stability) and 370C was tested by quantifying the 
leakage of the liposome-entrapped calcein from Vp-TSL prepared with different content of 
DOPE/DOPA. Calcein (100 mM) was encapsulated into the liposomes; at this concentration 
calcein fluorescence is self-quenched and has thus a low value. The calcein released after storage 
at 4°C for different time intervals (up to 50 days) and upon incubation at 37°C up to 24 hours was 
determined by measuring the increase in the fluorescence intensity with excitation and emission 
wavelengths of 490 nm and 520 nm with a spectrofluorimeter plate reader TECAN (using 96 
well black plates). The percentage of calcein released was calculated according to the formula 
introduced by Ho et al.13: 
 % calcein release = (F-F0)/(FTx-F0)×100        [1] 
where F0 represents the calcein fluorescence immediately after liposome preparation, F is the 
calcein fluorescence at a certain time point and FTx is the total fluorescence after adding 1% 
Triton X-100.  
 
 2.3.4. Serum stability of Vp-TSL 
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Calcein-loaded TSL with different PEG-lipids ratios were added to a 96-well black plate 
containing 20 % or 50 % serum in PBS and incubated at 37°C for 24 hours using a PHERAstar 
reader BMG Labtech equipped with a temperature controlled chamber. The increase in calcein 
fluorescence over time was measured and analysed using Mars software. The calcein release was 
determined using the above formula [1]. 
 
2.4. Determination of binding of VCAM-1 directed-TSL (Vp-TSL) to activated endothelial 
cells 
 
 2.4.1. Endothelial cell culture 
 
Human endothelial cells (EC), EA.hy926 line (purchased from American Type Culture 
Collection) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10 % fetal calf serum, 100 U penicillin, 100 µg streptomycin, 50 µg neomycin /ml, 100 µM 
hypoxanthine and 16 µM thymidine, at 370C in a 5 % CO2 incubator as previously indicated.19 
 
 2.4.2.VCAM-1 expression on activated EC membrane 
 
 The expression of VCAM-1 on the surface of EC after stimulation for 24 hours with 10 
ng/ml TNF-α was determined by flow cytometry using the appropriate antibodies and a standard 
flow cytometry protocol. 
 
 2.4.3. Binding of Vp-TSL to activated endothelial cells 
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Quiescent or TNF-α activated EC were fixed in 1% PFA and incubated for 1 h at room 
temperature with 0.25 µmol/ml Rhodamine-PE-labelled targeted Vp-TSL or non-targeted TSL in 
100 µl incubation solution containing 1% BSA in PBS. After one hour, to remove unbound 
liposomes, the cell/liposome suspensions were washed three times with cold PBS and then 
analyzed by flow cytometry (Gallios Flow Cytometer from Beckman Coulter). The specific 
binding of Vp-TSL to activated EC was assessed by a competitive binding assay. Briefly, Vp-
TSL were pre-incubated for 30 minutes with an excess of soluble VCAM-1 (10 µg/ml) and then 
incubated with EC. After 60 minutes the monolayers were washed three times to remove 
unbound liposomes and examined with an inverted fluorescence microscope (Olympus IX81). 
 
2.5. Evaluation of the specificity of binding of Vp-TSL  to activated EC surface and their 
fate 
 
 2.5.1. Vp-TSL binding studies by Surface Acoustic Wave (SAW) sensors 
 
The liposomal binding onto VCAM-1 was investigated by the mass-sensitive technology of 
Surface Acoustic Wave sensors using a SAM blue® device (SAW Instruments GmbH, Bonn, 
Germany) as described before 20 for Fc-tagged rh VCAM-1 immobilised on gold-coated sensors. 
The sensors were pre-incubated in an ethanol solution of 11-mercaptoundecanoic acid (10 mM) 
that formed a self-assembled monolayer. The terminal carboxyl groups were activated with a 
mixture of 200 mM N-ethyl-N-(dimethylaminopropyl)-carbodiimide (EDC) and 50 mM N-
hydroxysuccinimide (NHS) to bind 50 µg/mL VCAM-1 Fc-chimera. Excess of free activated 
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NHS esters was blocked by 1mM ethanolamine (pH 8.5). After immobilisation of the proteins, a 
15 min baseline equilibration in PBS was performed. The flow rate was adjusted to 40 µL/min.  
For binding experiments, the liposomes were used in dilution series between 10-10 M and 10-3M 
and binding events were measured as phase shifts of the acoustic wave. 
 
 2.5.2. Atomic Force Microscopy 
 
For topographic investigations, similar gold sensors as for SAW-sensor measurements were 
utilized. The technique employed was non-contact Scanning Polarization Force Microscopy 
(SPFM) that uses the electrostatic interactions between a charged tip (kept at 20 nm distance 
from the sample) and the sample whose topography is to be investigated. The SPFM scans were 
performed in AC mode with 5V amplitude bias applied between the tip and the sample at 3 kHz. 
The surfaces before and after hydration show no change in the topography. The microscope 
chamber had ~60% humidity so that the water film on the surface of the sensor would not 
evaporate too quickly. After the surface has been initially scanned, the liposomes were added and 
the excess solution was removed by absorption with a tissue paper from the side without 
touching the investigated surface.  
 
 2.5.3. Content release after binding of Vp-TSL to the activated EC surface 
 
 Static conditions. Calcein was used as a model compound for these experiments. The 
kinetics of calcein released from TSL (10 µM) endowed with 5 mol % PEG upon incubation 
with quiescent or TNF-α-activated EC (fixed in 1% paraformaldehyde) was followed for 1 to 24 
 13 
hours at 37°C by fluorescence measurements using a PHERAstar reader BMG Labtech equipped 
with a temperature controlled chamber. As control, conventional liposomes (CL) were used. The 
data obtained on the release in calcein fluorescence over time were analysed using Mars software 
and calculated using formula [1] described above.  
 Flow conditions. To mimic the in vivo conditions, we performed flow chamber 
experiments in which glass slides were covered with 0.2 µg rhVCAM-1 Fc chimera or with 
cultured quiescent or TNFα-activated EC. The slides were incorporated into a parallel plate flow 
chamber5 that was fixed on an inverted fluorescence microscope, and the flow medium (PBS, pH 
7.4) was driven at a shear rate of ~200 s-1. Different types of various prepared liposomes were 
added to a total volume of ~2 ml and the marker released was determined at different time points 
within 24 h. For this, 50 µL aliquots were collected and the fluorescence was quantified with a 
POLARstar Galaxy plate reader (BMG Labtech).  
 
2.6. Entrapment of CCR2 antagonist-Teijin- into targeted TSL (Vp-TSL-Tj) and its effects 
 
 2.6.1. Teijin entrapment into TSL 
 
The CCR2 antagonist, Teijin compound 1: (N-[2-[[(3R)-1-[(4-chlorophenyl)methyl]-3- 
pyrrolidinyl] amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide hydrochloride) was encapsulated 
into the aqueous phase of TSL by hydrating the lipid film with Teijin solution, at a drug:lipid 
ratio of 1:5, as described in section 2.2.1. The incorporation rate of Teijin was evaluated using 
UHPLC Agilent 1290 Infinity system with a column Zorbax SB C18 2.1x100 mm, 1.8 µm. The 
mobile phase was a mixture consisting of 43 % acetonitrile and 57 % 50 mM ammonium acetate 
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at pH 8. Detection of Teijin compound was done at 220 nm using a flow rate of 1 ml/min in 
isocratic mode at 25°C. 
 
 2.6.2. Teijin release from Vp-TSL-Tj after liposome binding to EC surface 
Activated cultured EC were incubated with Vp-TSL-Tj, non-targeted TSL (TSL-Tj) and VCAM-
1 recognizing peptide coupled to conventional liposomes encapsulating Teijin (Vp-CL-Tj) at 1 
µmol/ml and after defined times, the culture media were collected and the intact liposomes were 
separated from the released Teijin using the Millipore centrifugal filter units of 100 kDa cut off. 
Teijin concentration was determined by HPLC as described above and the release was calculated 
in relation to the start concentration of Teijin in liposomes before incubation. 
 
 2.6.3. Effect of Vp-TSL-Tj on human monocyte adhesion to human activated cultured EC  
 
Monocytes were isolated from human peripheral blood as described in supplementary material  
(please visit http://pubs.acs.org). The effect of Teijin compound 1 on monocyte adhesion to 
activated endothelium was monitored using EC seeded in 24-well plates and activated (24 hours) 
with 10 ng/ml TNF-α. Human monocytes were fluorescently labelled with 2'7'-bis (2-
carboxyethyl)-5(6)-carboxy fluorescein acetoxymethyl ester (BCECF-AM) as previously 
described.21  Activated EC were incubated for 1 hour with monocytes in the presence of different 
concentrations of Teijin either free or encapsulated into Vp-TSL-Tj, non-targeted TSL-Tj or into 
Vp-CL-Tj. The number of adhered monocytes was determined using a fluorescence microscope 
Olympus IX81 and CellSense Dimensions software. The percent inhibition of monocyte 
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adhesion to activated EC in the presence of free or liposome-encapsulated Teijin was calculated 
relative to control (monocytes incubated with activated EC).   
 
 2.6.4. Effect of Vp-TSL-Tj on monocyte transmigration through activated EC monolayer    
 
The efficacy of chemokine receptor inhibition by Vp-TSL-Tj on transmigration of human 
monocytes through activated EC was assessed by classical transmigration assay using Boyden 
chambers. The EC were seeded on the insert's filter and exposed for 24 hours with 10 ng/ml 
TNF-α. Activated EC were incubated with 100 µg/ml Teijin either free or encapsulated as Vp-
TSL-Tj or TSL-Tj or Vp-CL-Tj in the presence of BCECF-AM labelled monocytes. After 16 
hours, transmigration of monocytes was assessed using a serum gradient (1% FCS in the upper 
chamber and 10 % FCS in the lower chamber) and measuring the fluorescence of migrated 
monocytes attached to the filter as well as in the lower chamber. The percent inhibition of 
monocyte transmigration was determined relative to control (monocytes incubated with activated 
EC in the absence of free or Teijin-encapsulated liposomes).  
  
2.7. Animal studies 
 
 2.7.1. The animal models 
 
Male ApoE-/- mice (C57BL/6 genetic background) and C57BL/6 (wild type) mice from Charles 
River Laboratories were used. All animals had access to standard rodent diet, water ad libitum, 
and were kept in a temperature-controlled chamber at 24°C with a 12 h light/dark cycle. At seven 
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weeks of age, ApoE-/- mice were fed with a high-fat, cholesterol-rich (1%) diet for another six 
weeks. The experiments on mice had the approval of the Ethics Committee of our institution and 
were conducted in accordance with the EU guidelines, annexe to Directive 86/609, Appendix A 
of the European Convention for the protection of vertebrate animals used for experimental and 
other scientific purposes (ETS no. 123), Strasbourg, 2006.  
 
 2.7.2. Binding of Vp-TSL-Tj  to the aortic endothelium of ApoE-deficient mice  
 
These experiments were carried out by perfusing Vp-TSL or TSL (non-targeted liposomes) in 
situ in ApoE-/- mice kept for six weeks on Western-type diet, and as control on C57BL/6 mice, 
maintained on chow diet. The mice were anesthetized with ketamine/xylasine and then the 
vasculature was washed out of blood by injection into the left ventricle of PBS buffer using a 
peristaltic pump (infusion rate 2.5 ml/min). This was followed by administration of fluorescently 
(Rhodamine-PE) labelled Vp-TSL and TSL at a concentration of 1 μmol/ml. A gentle ligature 
placed on the abdominal aorta, allowed the close contact of liposomes with the vessel for 20 
minutes, after which the ligature was removed and the vasculature extensively washed (10 
minutes, 2.5 ml PBS/min.) to dispose of liposomes that were not bound to the vascular 
endothelium. Then, the aortas were excised and the fluorescence was measured by an IVIS 
Imaging System 200 (Caliper Life Sciences) using λex = 535 nm and λem = 620 nm. 
 
 2.7.3. Effect of Teijin on monocytes adhesion/infiltration into mouse aorta in situ 
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The effect of CCR2 antagonist on monocytes adhesion and infiltration into the atherosclerotic 
plaque was assessed as previously described.22 Briefly, RAW 264.7 cells (mouse 
monocyte/macrophage cell line) which reportedly express CCR2 receptors23 were fluorescently 
labelled by incubation (18 hours) with Rhodamine-labelled conventional multilamellar 
liposomes (1 µmol lipids/106 cells) and the cellular fluorescence was assessed by the 
fluorescence plate reader TECAN. Subsequently, labelled cells, pre-incubated or not with Teijin 
(40 µg/ml, for 30 minutes), were incubated in situ with the aortas of ApoE-deficient or C57BL/6 
mice (10x106 cells/mouse) using the same procedure as described in section 2.7.2. After 
thorough washing of the vasculature, the fluorescently labelled cells adhering to-, or infiltrated 
into the aorta were visualised by the IVIS Imaging System 200 (λex=535 nm; λem= 620 nm). 
 
2. 8. Statistical analysis 
 
The results were expressed as mean ± S.E.M. and all the experiments were performed at least in 
triplicates. Statistical evaluation was carried out by one-way analysis of variance between groups 
(ANOVA program of Origin). Differences were considered to be statistically significant when 
p<0.05.  
 
3. Results 
 
3.1. Preparation and characterization of VCAM-1 targeted TSL (Vp-TSL) 
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We prepared PEG-stabilized TSL consisting of a balanced bilayer mixture of DOPE, DOPA and 
a PEGylated phospholipid used for coupling of homing devices. A series of liposomes that 
varied slightly in the lipid composition were obtained by varying fractions of DOPA or the PEG 
derivative, as outlined in supplementary Table 1 (please visit http://pubs.acs.org). 
 For targeting the activated vascular endothelium we choose the surface exposed protein 
VCAM-1 that reportedly is considered the most promising target, characteristically expressed 
under inflammatory conditions.4,24,25 A peptide with affinity for VCAM-1 was covalently 
coupled via maleimide to the distal end of functionalized PEG-phospholipids incorporated into 
liposomal bilayers. HPLC results showed no detectable free peptide in the liposome preparations 
indicating a coupling efficiency of ~10 µg peptide/µmol phospholipid. There were no significant 
differences between peptide-coupled TSL (Vp-TSL) and non-targeted TSL with respect to the 
average hydrodynamic diameter (immediately after preparation or during storing periods) that 
was around 130 nm (127.58 ± 18.88 nm, n=8) and had a unimodal size distribution (as shown by 
the polydispersity index) always smaller than 0.2.   
The entrapment stability of the different liposomal preparations was determined following 
calcein release as a function of time, temperature, storage in PBS or PBS supplemented with 
serum. We determined the release of calcein from TSL composed of 5 mol % PEG and different 
concentration of DOPA in the phospholipid bilayer (supplementary Table 1, please visit 
http://pubs.acs.org) after incubation in buffer (at 4°C) for time intervals up to 50 days (Figure 
1A) and for up to 24 hours at 37°C (Figure 1B). The experiments showed that the lowest calcein 
release was determined for Vp-TSL with 35% DOPA content; at this concentration, no 
noticeable increase of calcein released within 50 days of storage at 4°C was detected. Moreover, 
the release of calcein from Vp-TSL with 35% DOPA content at 37°C was ~ 20%, whereas other 
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formulation such as TSL with 10 mol % DOPA released more than 70 % calcein in the same 
conditions (24 hours).  
 
It is accepted that a certain fraction of PEG-PE is essential to avoid destabilization and to provide 
sufficient stability of liposomes in a serum environment. Conversely, PEG-PE antagonizes the 
target-sensitive release mechanism. Thus, to investigate the relation between PEG-concentration 
and serum stability of the prepared liposomes, calcein release from TSL with different content of 
PEG-lipids was evaluated at 37°C in PBS containing 20 % or 50 % serum. Figure 1 C and D 
summarize the percent release of calcein from TSL (DOPE: DOPA: PEG-DSPE: Mal-PEG-
DSPE) composed of 35 mol % DOPA and different concentration of phospholipid derivatives of 
PEG [from 1 to 5 mol % PEG, please see also supplementary Table 1 available at 
http://pubs.acs.org) 
We observed that the percent of calcein released after incubation of TSL in 20 % serum 
decreased as the concentration of PEG-lipids into bilayers increased. Thus, a burst release of 
calcein (~ 65 %) was detected after 1 hour incubation in serum of TSL containing 1 mol % PEG, 
whereas in the case of TSL with 5 mol % PEG the percent release was ~ 10 %. After 24 hours, 
TSL with 1 mol % PEG released over 95 % of encapsulated calcein while for TSL with 5 mol % 
PEG the calcein released was ~60 %. Incubation of TSL with 50 % serum determined a high 
destabilization of TSL causing at 1 hour a release of calcein from TSL with 1 mol % PEG of      
~75 % and from TSL with 5 mol % PEG of ~ 40 %. At 24 hours, the release of entrapped calcein 
from TSL with 1 mol % PEG was ~ 80 % and from TSL with 5 mol % PEG, ~ 70 %. 
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 Based on the above results on the stability of stored TSL in buffer and in sera, for all 
further functional studies of targeted release, the nanoparticles having in composition 35 mol% 
DOPA and 5 mol % PEG were employed.   
 
3.2. VCAM-1 directed TSL (Vp-TSL) target specifically activated endothelial cells 
 
The specificity of binding of Vp-TSL to activated EC was investigated by flow cytometry and 
fluorescence microscopy. First, we assessed and confirmed by flow cytometry that as expected, 
in our experimental conditions TNF-α –activated EC express VCAM-1 on their surface 
(supplementary Figure 1). The experiments performed demonstrated that non-targeted TSL do 
not recognize or bind to a very low level to activated EC (<1%). In contrast, as shown in Figure 
2A, Vp-TSL bound specifically to activated EC and the binding was significantly higher 
compared to the binding to non-activated EC (40 % versus ~10 %, respectively). The specific 
binding of Vp-TSL to activated EC (Figure 2B) was completely blocked by pre-incubation of 
Vp-TSL with an excess of soluble recombinant VCAM-1 (10 µg/ml) prior to exposure to the 
activated EC (Figure 2C). Together these data indicated clearly the specificity of Vp-TSL to 
TNF-α activated EC. 
 
3.3. Fate of Vp-TSL after the specific binding to endothelial VCAM-1 
 
 The triggered release of a drug payload from TSL at the target site is likely induced by a 
liposomal fusion with the target surface or by an aggregation process inducing massive 
liposomal destruction. In order to investigate whether the TSL selected above show such as 
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destruction, we followed the fate of liposomes after binding to a simulated target surface 
applying either a biosensor approach or atomic force microscopy.  
 The liposome binding and its fate after binding onto a VCAM-1 covered sensor was 
investigated by mass-sensitive technology of Surface Acoustic Wave. It became evident from the 
phase shifts that Vp-TSL injected in increasing concentrations, bind to the target protein (Figure 
3A) but not to the plain TSL lacking the peptide (Figure 3C). Most interestingly, Vp-TSL induce 
a certain increase in oscillation amplitude after the initial binding, which indicated a decreased 
surface viscoelasticity due to an intensive surface contact of the liposomes, most likely a 
flattening or fusion at the target surface (arrow in Figure 3B). This effect was not achieved when 
non-targeted TSL or VCAM-1 targeted liposomes of conventional lipid composition were tested. 
The results strongly suggested the flattening or fusion of the Vp-TSL at the target surface. 
 Using Scanning Polarization Force Microscopy (SPFM) we obtained scans as 2D and 3D 
images of VCAM-1 covered gold sensor surface subsequent to the addition of Vp-TSL (Figure 
3D and insert). The liposomes appeared as structural features of 150-250 nm diameter adherent 
to the VCAM-1 functionalized surface. Most of the liposomes collapsed immediately after the 
interaction with VCAM-1 covered surface; at times, liposome in the process of deformation were 
observed next to a still intact one. As a parameter to follow the shape changes, the volume of the 
liposomes was estimated from the topography images by integration under the marked area, the 
volume between the liposome surface and the plane z = zmin, where zmin is the minimum value of 
height occurring in the marked area (Figure 3F and G). The difference in height between 
liposome and the sensor surface was measured and integrated over the 110 nm high liposome 
(non-collapsed liposome marked with red for measurement, Figure 3F) and over the collapsed 
liposome (marked with red for measurement, Figure 3G). The estimated volume of the 110 nm 
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high liposome is 0.00177 μm3, while the estimated volume of the collapsed liposome is 0.00179 
μm3. Since the volume of a liposome after collapsing is not expected to change, as the same 
amount of liquid is present, only rearranged as a film instead of a vesicle, these measurements 
indicated that the image in Figure 4D portrays a collapsed and a non-collapsed liposome. The 
expected volume of a liposome can also be calculated for a given diameter. Using the volume 
formula of a sphere (4πR3/3) we calculated that a 150nm in diameter spherical liposome would 
have the same approximate volume (0.00176 μm3) an indication that the topographical details on 
the sensor's surface represent the investigated liposomes. In contrast, no interaction with BSA 
covered surface could be detected (Figure 4E) confirming that the specific binding of TSL is a 
prerequisite for their deformation and potential cargo release. 
 
3.4. Upon binding, Vp-TSL release their content on the surface of activated EC 
 
A prerequisite for a suitable high activity at target sites is the destabilization of the liposomes 
after binding to the target cells and the resulting release the encapsulated cargo. To check 
whether this property applies to our liposome preparations we performed experiments to 
determine the kinetics of calcein release from 10 µM TSL-1 incubated with quiescent or TNF-α 
activated EC (slightly fixed in 1% paraformaldehyde) for 1 to 24 hours at 37°C under static and 
flow conditions. Under static conditions, the fluorescence measurements indicated that Vp-TSL 
upon binding to activated EC released (at all times studied) the highest amount of encapsulated 
calcein having values of ~15% and ~74% after 1 and 24 h, respectively (Figure 4 A and B). In 
contrast, control liposomes (Vp-CL) released only 6% of the encapsulated marker after 24 h of 
incubation with activated EC. 
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 In flow conditions (flow chamber experiments), the release of calcein was determined 
upon incubation of non-targeted and targeted Vp-TSL with VCAM-1 Fc chimera or with 
quiescent or TNFα-activated EC placed on glass slides and incorporated into a parallel plate flow 
chamber. The flow medium, (PBS, pH 7.4) was driven at a shear rate of ~200 s-1 and the 
fluorescence of calcein release was determined at different time points for 24 hours. Whereas 
Vp-TSL released nearly 80% of their payload at 24 hours after binding to immobilized VCAM-
1, only 60% has been released by TSL lacking the homing peptide (Figure 4C). A similar 
difference was also detected in the experiments in which the release of calcein upon binding of 
Vp-TSL to activated and non-activated EC were compared; in the latter case, the release rate was 
significantly lower compared to activated EC (Figure 4D). 
 
3.5. Teijin is released after interaction of Vp-TSL-Tj with activated EC and inhibit 
monocyte adhesion 
 
Teijin compound 1 was selected as pharmacological tool to search for the interference with the 
local inflammatory reactions in atherosclerosis. The CCR2 expression by EC and human PBMC 
was assessed by flow cytometry as outlined in the Supplementary Figure 2.  
Furthermore, the hydrophilic properties of Teijin and its solubility in water are characteristics that 
should assure a comparable release as shown above for calcein. The encapsulation efficiency of 
Teijin into TSL was determined by HPLC after separation of entrapped from free Teijin; the 
calculated entrapment was about 75 µg Teijin/µmol liposomes.  
 
 3.5.1. Teijin is released from Vp-TSL-Tj after binding to activated EC surface 
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The release characteristics of Teijin fromVp-TSL-Tj were in line with those obtained with the 
marker molecule, calcein, indicating a higher release in comparison with the amount liberated 
from conventional Vp-CL-Tj. The concentration of Teijin released from different types of 
liposomes after their incubation with activated EC was determined by HPLC and the release was 
calculated in relation to the initial concentration of Teijin entrapped into liposomes (before 
incubation with EC). Upon incubation with activated EC, the highest release of Teijin was 
obtained in the case of Vp-TSL-Tj where the calculated values were ~43 % after 1 hour and 
more than 78 % after 6 hours of incubation, while for non-targeted TSL (TSL-Tj) and targeted 
CL (Vp-CL-Tj) the figures obtained were ~30 % and ~7 % after 6 hours, respectively (Figure 5). 
 
 3.5.2. Vp-TSL-Tj inhibit monocyte adhesion and transmigration through activated EC 
monolayer  
 
The adhesion of monocytes to activated EC was inhibited by ~45% in the presence of free Teijin 
at 100 µg/ml concentration (Figure 6A). In the case of targeted TSL, the concentration of 100 
µg/ml Teijin incorporated into Vp-TSL-Tj determined the maximal inhibition of monocyte 
adhesion of ~28%; a further increase in the concentration does not enhance the effect. However, 
the inhibition by TSL-Tj or Vp-CL-Tj was significantly lower (13% and 7%, respectively). 
The efficacy of chemokine receptor inhibition by Vp-TSL-Tj on transmigration of human 
monocytes through human activated EC was assessed by the classical transmigration assay using 
the Boyden chambers. The TNF-α activated EC seeded on the insert's filter were incubated with 
100 µg/ml of either free Teijin or Vp-TSL-Tj, TSL-Tj and Vp-CL-Tj in the presence of calcein-
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AM labelled monocytes. In all experimental conditions, the percent inhibition of monocyte 
transmigration in the presence of Teijin, either free or incorporated into different types of 
liposomes, was determined relative to control (monocytes incubated with activated EC in the 
absence of free or encapsulated Teijin) by measuring the fluorescence of the cells in the lower 
chamber and trapped to the filter. A significantly higher inhibition of monocyte transmigration 
was obtained for Vp-TSL-Tj (~ 53%) as compared to non-targeted TSL-Tj (~32 %) and Vp-CL-
Tj (~18 %). 
 
3.6. Animal Studies 
 
The in vivo effect of Teijin and targeted liposomes were investigated on ApoE-/- mice. First, we 
searched whether Teijin is functional in Apo E-/-  mice by following the effect of pre-treatment 
of  monocyte with Teijin on their adhesion/infiltration into the aorta of mice. Second, we tested 
whether Vp-TSL recognizes and bind specifically to activated aortic EC in ApoE-/- mice. 
Further preliminary experiments following the effect of the Vp-TSL-Tj treatment of ApoE-/- 
mice showed that atherosclerotic lesions area was significantly reduced in treated animals (data 
not shown).  
 
 3.6.1. Teijin inhibits monocyte/macrophage (RAW 264.7 cell line) infiltration into mouse 
aorta 
 
The effect of Teijin on the adhesion of monocytes to EC was evaluated in situ by pre-incubation 
of RAW 264.7 cells with CCR2 antagonist and determining their adhesion and accumulation in 
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the aortas of ApoE-/- mice using an IVIS imaging system. It was found that compared to the 
sizeable accumulation of fluorescently labelled monocytes in the aorta of ApoE-/- mice, pre-
incubation with Teijin decreased notably the binding and the infiltration of monocytes into the 
aorta (Figure 7). No infiltration of monocytes was detected in the aorta of C57BL/6 mice in the 
absence or the presence of Teijin. The results indicated that Teijin operates as an inhibitor of 
monocytes adhesion/infiltration to the aorta of mice.  
 
  3.6.2. Vp-TSL bind specifically to the aorta of ApoE -/- mice 
 
The binding of Vp-TSL to the aortas of ApoE-deficient and C57BL/6 mice was investigated after 
in situ administration of Rhodamine-PE labelled liposomes and extensive washing to remove 
non-bound liposomes. The aortic arches, thoracic and abdominal aortas were harvested and 
viewed by fluorescent optical imaging employing an IVIS system. The images were quantified 
for fluorescent radiant efficiency [fluorescence emission radiance per incident excitation 
intensity: (p/sec/cm2/sr)/(μW/cm2)] using region-of-interest (ROI) function of the Living Image 
4.3.1. software. The results revealed a higher binding to the aorta of Apo E-/- mice for Vp-TSL  
(at a radiant efficiency of 6.25 ± 0.74 × 108) as compared to non-targeted TSL whose binding 
was significantly lower (4.75 ± 0.25× 108); no binding to the aorta of control C57BL mice was 
detected (Figure 8).  
 
Discussion 
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Despite of the great progress in developing new technologies for diagnosis and/or therapeutics, 
the cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality in the 
world. The inflammatory process is a common early event in atherogenesis, characterized by the 
expression of a specific array of cell adhesion molecules and chemokines on the endothelium 
that attract particular immune cells (e.g. monocytes, lymphocytes) to the developing 
atherosclerotic plaque.1 Since chemokines are critically involved in the development of 
atherosclerosis, the design of a targeted delivery nanosystem able to carry inhibitors of 
chemokine/chemokine receptor interaction at the surface of "inflamed" endothelium is desirable. 
Such a delivery system may constitute a therapeutic option to achieve a reduction of monocytes 
accumulation into vascular wall and consequently, to slow down or to prevent the inflammatory 
process.  
To design a drug carrier system which possesses vascular targetability combined with a triggered 
drug release at the target site, we adapted the principle of the target-sensitive liposomes (TSL) 
described by Leaf Huang and collaborators12,13,14,26,27,28 to PEGylation to guarantee long 
circulation in the blood.  During atherosclerosis VCAM-1 has been shown to be over-expressed 
at the endothelial surfaces.4,24,25 , therefore, the attachment of a peptide with high affinity for 
VCAM-1 to the distal ends of PEG present in liposomes bilayers endows specificity of TSL for 
activated EC. Previously, TSL obtained by stabilization of unsaturated DOPE into bilayers using 
antibodies or peptide derivatives of fatty acids (palmitic acid) were employed for the delivery of 
antiviral agents12-14,26-28 or streptokinase.29,30   
We performed optimization studies by varying fractions of DOPA or the PEG-DSPE derivatives 
to establish the liposomes composition that best guarantee the stability of the targeted carrier 
system in the blood until they reach the molecular target on the surface of activated EC. Based 
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on these results we chose the TSL having in composition 60 mol % DOPE, 35 mol% DOPA and 
5 mol % PEG to be employed for all further functional studies of targeted release, as this 
composition assure the best stability in serum and at storage. These liposomes were able to 
efficiently encapsulate Teijin compound 1, an antagonist of chemokine receptor CCR2 (Vp-TSL-
Tj) and deliver specifically at the surface of activated EC. The results of the competitive binding 
assay experiments revealed that Vp-TSL bind selectively and specifically to activated EC. 
Furthermore, we could provide an insight into the behaviour of Vp-TSL after binding to the 
target VCAM-1 by biosensor or SPFM measurements. These suggest a flattering or fusion of the 
TSL at the target surface as a prerequisite for their deformation-triggered release of the entrapped 
compounds. 
In addition, in vitro evaluation of the release of entrapped calcein from TSL incubated with 
immobilized rhVCAM-1 or EC under static or flow conditions revealed a higher amount of 
release in the case of Vp-TSL incubated with rhVCAM-1 coated slides. Similarly, activated EC 
under static or flow conditions revealed a higher amount of release in the case of Vp-TSL at all 
times studied that was in contrast with non-targeted TSL and conventional Vp-CL liposomes. 
Only one previous study investigated the effects of different amount of PEG-derived 
phospholipids on the activity of target-sensitive liposomes.31 Ng et al showed that target-induced 
destabilization does not take place when the amounts of PEG2000-DOPE higher than 0.3 mol % 
are used for TSL preparation. On the contrary, our Vp-TSL composed of 5 mol % PEG2000-
DSPE bound to activated EC and released the highest amount of encapsulated calcein with 
values of ~15% and ~74% after 1 and 24 h, respectively in comparison with non-targeted TSL 
and conventional liposomes. The percent of Teijin released at the surface of activated EC from 
Vp-TSL-Tj was ~ 45 % at 1 h of incubation. A possible explanation for the difference between 
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our results and previous study31 could be based on the different preparation of liposomes. Ng et 
al coupled an antibody targeting p-glycoproteins to N-glutarylphosphatidylethanolamine (N-glut-
PE) to the liposomal surface. Thus, the antibody could be masked by the increasing amount of 
PEG, leading to a reduced binding to the target and consequently, a reduced triggering of the 
release. In contrast, coupling the homing device to the distal ends of PEG, as performed in our 
study, appears to be the favourable condition to obtain both, sufficient target accessibility and a 
triggered cargo release apart from acceptable storage stability. Our results on serum stability 
confirm that increasing concentration of PEG-DSPE decrease the serum induced calcein release. 
However, we observed a higher release after interaction with serum for TSL with 1 mol % 
PEG2000-DSPE (1 hour of incubation with 20 % and 50 % serum determined ~65 %  and ~75 % 
release) in comparison with a release below 10 % for TSL with 1 mol % PEG2000-DOPE in 10 % 
and 75 % serum, observed previously31.  
The water-soluble CCR2 antagonist was encapsulated into the aqueous compartment of TSL at a 
concentration of ~75 µg Teijin/µmol liposomes, as indicated by HPLC measurements. The 
functional effect of Teijin, free or entrapped into liposomes (Vp-TSL-Tj) on monocyte adhesion 
and transmigration was followed in vitro, using TNF-α activated EC (aEC). We detected a 
higher reduction of human monocyte adhesion to activated EC when the cells were incubated in 
the presence of Vp-TSL-Tj in comparison with aEC incubated with TSL-Tj or Vp-CL-Tj. These 
data are indicative of the specificity of Vp-TSL-Tj and the release at the target surface of a 
higher amount of Teijin as compared to non-targeted TSL and Vp-CL-Tj. The inhibition of 
monocyte adhesion induced by cell treatment with free Teijin is higher than using any liposomal 
system entrapping Teijin. This finding is clearly related to the lower and slower Teijin release 
from the liposomes compared to the free drug, which is directly available. However, these 
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experimental conditions neglect the physiological situation of blood flow and the potential 
benefit of the sustained local release of the drug from the liposomes. In the case of monocyte 
transmigration through aEC, a process that was followed for 16 hours, Vp-TSL-Tj generated an 
inhibition of transmigration that was superior to that obtained with same amount of free Teijin 
or TSL-Tj or Vp-CL-Tj. This result indicates that Vp-TSL-Tj besides releasing Teijin, also bind 
and block VCAM-1 that is actively involved in monocyte transmigration32, thus augmenting the 
percent inhibition of monocyte transmigration.  
To test whether the Vp-TSL are functional in vivo we employed the ApoE-/- mice. Previous 
studies showed that VCAM-1 is overexpressed on EC covering the developing atherosclerotic 
plaque.33 We found that in comparison with non-targeted liposomes, Vp-TSL bind specifically 
and to a high extent to the aorta of ApoE-deficient mice, recommending VCAM-1 as a reliable 
target for liposomes carrying chemokine receptor antagonists. In addition, we tested whether the 
CCR2 antagonist is functional in mice by following the effect of Teijin on mouse 
monocyte/macrophage (RAW 264.7 cell line) adhesion/infiltration into the aorta of ApoE-
deficient mice in situ. The results of these experiments revealed that pre-treatment of monocytes 
with Teijin inhibited monocytes adhesion/infiltration into the aorta indicating that locally 
delivered CCR2 antagonist could function in reducing the monocyte infiltration into 
atherosclerotic plaque.  
    
Conclusion 
 
The newly developed VCAM-1 directed PEGylated target-sensitive liposomes encapsulating 
Teijin, a CCR2 antagonist bind specifically to the surface of activated EC, release the entrapped 
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drug and are functional in inhibiting the adhesion and transmigration of monocytes to/through 
activated EC. This study is the first evidence that a compound that interferes with 
chemokine/chemokine receptor interactions can be efficiently incorporated into designed 
liposomes for specific targeting of activated vascular endothelium. These novel findings hold 
great promises in reducing the chemokine-dependent inflammatory processes in many 
inflammation-related diseases, including atherosclerosis.  
 
 
 
 
Supporting information available 
 
The protocol for isolation of monocytes from human peripheral blood, the table containing the 
lipid composition of various formulations of target-sensitive liposomes (TSL) and the flow 
cytometry data on the expression of VCAM-1 and CCR2 on endothelial cells and of CCR2 on 
human monocytes are provided. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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